Last $0.07 USD
Change Today -0.015 / -17.65%
Volume 63.8K
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

urologix inc (ULGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/12/14 - $0.20
52 Week Low
12/30/14 - $0.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UROLOGIX INC (ULGX)

Related News

No related news articles were found.

urologix inc (ULGX) Related Businessweek News

No Related Businessweek News Found

urologix inc (ULGX) Details

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy urethral tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate and destroys prostate tissue that reduces constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

61 Employees
Last Reported Date: 09/19/14
Founded in 1991

urologix inc (ULGX) Top Compensated Officers

Chief Executive Officer, Interim Chief Financ...
Total Annual Compensation: $200.0K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2014.

urologix inc (ULGX) Key Developments

Urologix, Inc. Announces Revenue Guidance for Second Quarter Ended on December 31, 2014

Urologix, Inc. announced revenue guidance for its second quarter of fiscal year 2015 ended on December 31, 2014. For the, second quarter of fiscal year 2015 revenue is expected to be approximately $3.1 million, up approximately 2% sequentially from the first quarter of fiscal year 2015. The second quarter revenue was down approximately 19% compared to the second quarter of the prior fiscal year, which was the last full quarter of operations before the Company restructured its sales and operations in the second half of fiscal year 2014.

Urologix, Inc. Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2014; Provides Cash Flow Guidance for the Fiscal 2015

Urologix, Inc. reported unaudited earnings results for the first quarter ended September 30, 2014. For the quarter, sales were $3,021,000 against $3,779,000 a year ago. The decreases in Revenues were driven by reduced sales of both CTT and Prostiva products. Operating loss was $241,000 against $1,162,000 a year ago. Loss before income taxes was $432,000 against $1,322,000 a year ago. Net loss was $437,000 against $1,334,000 a year ago. Net loss per common share--basic and diluted was $0.02,000 against $0.06,000 a year ago. Net cash used in operating activities was $170,000 against $734,000 a year ago. Purchases of property and equipment were $1,000 against $2,000 a year ago. Purchases of intellectual property were $2,000 against $3,000 a year ago. For the fiscal 2015, the company expects positive cash flow from operations and support building upon the evidence demonstrating the cost-effectiveness of in-office BPH technologies. The company expected some lower sales volume in 2015 fiscal year with its new sales deployment model and organizational structure, but believes the restructuring has allowed to focus on a stronger base of business to first stabilize and then begin to expand upon.

Urologix, Inc. to Report Q1, 2015 Results on Nov 04, 2014

Urologix, Inc. announced that they will report Q1, 2015 results at 4:00 PM, Central Standard Time on Nov 04, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULGX:US $0.07 USD -0.015

ULGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $14.74 USD -0.22
Medifocus Inc C$0.08 CAD +0.01
Olympus Corp ¥4,160 JPY -30.00
Uroplasty Inc $1.20 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation ULGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROLOGIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at